Use of aminoacetonitrile compounds for the treatment of infection and disease

A method for the treatment of cancer, or one or more mTOR pathway related diseases, the method comprising administering to a patient in need thereof an amount of a compound of formula (I):

• or a pharmaceutically acceptable salt or solvate thereof, sufficient to achieve a plasma concentration of said compound and/or a metabolite thereof of about 0.005 μM, about 0.01 μM, about 0.05 μM, about 0.1 μM, about 0.2 μM, about 0.3 μM, about 0.4 μM, about 0.5 μM, about 0.6 μM, about 0.7 UM, about 0.8 μM, or about 0.9 μM,
• wherein
• R1, R2 and R3 and R5 are each independently selected from H, alkyl, halogen, —CF3 or —CN;
• R4 and R6 are each independently selected from H, alkyl, halogen, alkoxy, —CF3, —OCF3, —SO2CF3, —SOCF3 or —SCF3;
• X is heteroatom, N(alkyl) or NH;
• and
• n is 1 to 20;
• and
• wherein the cancer is selected from bladder cancer, kidney cancer, liver cancer, lung cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, stomach cancer, thyroid cancer, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma, Burkett's lymphoma, myelodysplastic syndrome, rhabdomyosarcoma, astrocytoma, neuroblastoma, schwannoma, seminoma, teratocarcinoma, osteosarcoma, or Kaposi's sarcoma, and
• wherein the mTOR pathway related disease is selected from Alzheimer's disease, Huntington's disease, motor neurone disease/amyotrophic lateral sclerosis, Parkinson's disease, age-related diseases, diseases related to transplant rejection, chronic inflammatory diseases, diseases related to glycogen storage, systemic lupus, diseases related to inflammation and immune activation, anaemia, leucopenia, thrombocytopenia, diseases related to stent coatings, renal insufficiency, obesity, diabetes/insulin resistance, diseases related to non-alcoholic fatty liver, polycystic kidney, fibrosis, or vial infection.